ProShares UltraPro Nasdaq Biotechnology
UBIO
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Leveraged
- Address
- IPO Date
- Jun 22, 2015
- CIK
- 0001174610
- Similar Companies
- Business
- ProShares UltraPro Nasdaq Biotechnology (UBIO) is an exchange-traded fund that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq Biotechnology Index. The fund provides leveraged exposure to U.S.-listed biotechnology companies primarily engaged in the research, development, production, and marketing of pharmaceuticals, biotechnology, and life sciences; it achieves this objective by investing in financial instruments such as swaps on the Nasdaq Biotechnology Index, exchange-traded funds, and biotechnology stocks through derivatives and direct holdings. With approximately 211 holdings, the top 10 positions represent over 53% of assets, targeting large- and mid-cap biotech firms in developed North American markets. Headquartered in Bethesda, Maryland, ProShare Advisors LLC, the fund's sponsor, was established in 1999 as part of ProShares Trust and manages one of the largest lineups of leveraged and inverse ETFs. UBIO operates globally through U.S. exchanges like Nasdaq, serving institutional and retail investors seeking amplified daily returns from the biotechnology sector. Launched on June 23, 2015, the fund has maintained its core strategy without major structural changes or closures, unlike some prior ProShares leveraged biotech products considered for liquidation in 2020. Recent activity for ProShares includes thematic ETF launches such as crypto-related funds in 2025 with partners like Amplify, alongside ongoing expansions in leveraged products, though no specific partnerships, acquisitions, funding rounds, or operational shifts directly impact UBIO in the last 1-2 years. Assets under management stand at approximately $27 million, with quarterly distributions and a net expense ratio reflecting standard leveraged ETF costs.